Table 2 The top three answers for each qualitative question
Items | Responders |
|---|---|
(N = 130) | |
What are the causes of seizure aggravation or increased frequency in patients for case review? | |
 Withdrawal, decreased dosage, alternative ASMs, and ASMs shortage, n (%) | 106 (81.5) |
 Lifestyle change, n (%) | 35 (26.9) |
 Psychological disorders (anxiety and fear), n (%) | 24 (18.5) |
What are the reasons for the aggravation of psychological disorders (e.g. anxiety or depression) in patients for case review? | |
 ASMs unavailability; ASMs shortage, n (%) | 71 (54.6) |
 Fear of suffering from COVID-19, n (%) | 53 (40.8) |
 Irregular lifestyle, n (%) | 19 (14.6) |
Why didn’t the patients come for regular case review albeit they should? | |
 Quarantine and the traffic restrictions, n (%) | 96 (73.8) |
 Fear of suffering from COVID-19, n (%) | 44 (33.8) |
 Epidemic of COVID-19, n (%) | 20 (15.4) |
Why were the patients unable to obtain ASMs? | |
 Breakdown of ASMs supply systems, n (%) | 67 (51.5) |
 Quarantine and traffic restrictions, n (%) | 62 (47.7) |
 Suspension and limitations of clinical services, n (%) | 9 (6.9) |
What are the urgent needs for people with epilepsy in this COVID-19 crisis? | |
 Maintaining regular ASMs supply, n (%) | 97 (74.6) |
 Providing consultation, especially ASMs treatment instruction, n (%) | 90 (69.2) |
 Psychological counsultation, n (%) | 38 (29.2) |